Catalyst Event
Moderna Inc (MRNA) · Other
From Akros U.S. Large Cap 500 Protective Allocation Monthly Index (A500PAM)
6/8/2026, 12:00:00 AM
Announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) authorized a Phase 1/2 clinical study for mRNA-4194. This regulatory milestone is expected to drive a >5% price impact, expected.
Korean Translation
2026년 6월 8일, 영국 MHRA의 mRNA-4194 1/2상 임상 연구 승인 발표로 5% 이상의 주가 영향이 예상됨.
Related Recent Events
Synopsys Inc (SNPS) · Other
An investor day to discuss long-term financial targets and strategy is scheduled.
9/30/2026, 12:00:00 AM
Broadcom Inc (AVGO) · Earnings Release
Broadcom's Q3 2026 earnings release on September 3, 2026. This event is expected to have a medium impact as it will provide critical updates on AI revenue growth, scheduled
9/3/2026, 12:00:00 AM
NetApp Inc (NTAP) · Earnings Release
Next quarterly earnings for Q1 fiscal year 2027 are scheduled.
8/26/2026, 12:00:00 AM
HEICO Corp (HEI) · Earnings Release
Next quarterly earnings for Q3 2026 are scheduled to be reported on 2026-08-24, with analysts forecasting an EPS of $1.46; low importance is estimated as market impact is typically limited for scheduled announcements, scheduled.
8/24/2026, 12:00:00 AM
Walmart Inc (WMT) · Earnings Release
Walmart is scheduled to release its Q2 FY2027 earnings results on 2026-08-20, scheduled. Medium importance is estimated as earnings releases typically trigger significant market volatility.
8/20/2026, 12:00:00 AM
Microsoft Corp (MSFT) · Other
Microsoft declared a quarterly dividend of $0.91 per share with an ex-dividend date of August 20, 2026, scheduled.
8/20/2026, 12:00:00 AM